Comprehensive medication guide to Nusinersen including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Spinraza is billed as a medical benefit (not pharmacy benefit) under HCPCS code J2326. Commercial insurance requires prior authorization; out-of-pocket costs depend on plan coinsurance and deductibles. Medicare Part B covers Spinraza with 20% coinsurance after deductible. Biogen's SMA360° program offers co-pay assistance for commercially insured patients (potentially $0 out-of-pocket). Medicare patients can seek assistance through the HealthWell Foundation and NORD.
Estimated Cash Pricing
Spinraza (nusinersen) has a list price of approximately $125,000 per injection. First-year treatment costs approximately $750,000 (6 injections); ongoing maintenance costs approximately $375,000 per year (3 injections). No generic is available. Standard retail pharmacy coupons do not apply as this drug is dispensed through specialty pharmacies to treatment centers.
Medfinder Findability Score
72/100
Summarize with AI
On this page
Nusinersen, marketed as Spinraza by Biogen, is the first FDA-approved disease-modifying therapy for spinal muscular atrophy (SMA). It received FDA approval in December 2016 and is now approved in more than 71 countries worldwide. Nusinersen is an antisense oligonucleotide (ASO) — a short, synthetic strand of genetic material — designed to treat SMA caused by mutations in the SMN1 gene.
SMA affects approximately 1 in 10,000 newborns and is a leading genetic cause of infant mortality. It causes progressive loss of motor neurons — the nerve cells that control muscles — resulting in progressive muscle weakness and wasting. Before the approval of nusinersen, there were no disease-modifying treatments for SMA; management was limited to supportive care.
Nusinersen is approved for both pediatric and adult patients across all SMA types (1, 2, 3, and 4). In March 2026, the FDA also approved a new High Dose Regimen of Spinraza (50 mg loading dose / 28 mg maintenance dose), in addition to the existing 12 mg low-dose regimen, expanding treatment options for patients and providers.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
SMA is caused by mutations or deletions in the SMN1 gene, which normally produces survival motor neuron (SMN) protein. Humans also carry a backup gene — SMN2 — which is nearly identical to SMN1 but produces mostly non-functional, truncated SMN protein due to the natural skipping of exon 7 during RNA splicing.
Nusinersen works as an SMN2-directed antisense oligonucleotide. It binds to the SMN2 pre-mRNA and blocks the molecular signal that causes exon 7 to be skipped. This correction allows SMN2 to produce full-length, functional SMN protein — effectively compensating for the missing SMN1 gene. The result is increased SMN protein levels in motor neurons, which slows or stops their degeneration.
Because motor neurons are located in the spinal cord and protected by the blood-brain barrier, nusinersen must be delivered intrathecally — directly into the cerebrospinal fluid (CSF) surrounding the spinal cord via lumbar puncture. It has a half-life of 135-177 days in CSF, which is why maintenance dosing is only required every 4 months. Nusinersen does not interact with the CYP450 enzyme system and is eliminated primarily through urinary excretion.
12 mg/5 mL (2.4 mg/mL) — intrathecal injection
Low Dose Regimen: 4 loading doses (days 1, 15, 29, 63), then 12 mg maintenance every 4 months
50 mg/5 mL (10 mg/mL) — intrathecal injection
High Dose Regimen loading dose (FDA-approved March 2026): 2 doses 14 days apart
28 mg/5 mL (5.6 mg/mL) — intrathecal injection
High Dose Regimen maintenance dose (FDA-approved March 2026): once every 4 months
Nusinersen is not available at retail pharmacies. It is a specialty biologic distributed exclusively through specialty pharmacy networks directly to certified treatment centers — hospitals, academic medical centers, and specialized neurology and neuromuscular disease clinics. As of 2026, there is no active FDA drug shortage for nusinersen.
Access challenges for nusinersen are primarily administrative and financial rather than related to physical supply. The main barriers include obtaining prior authorization from insurance (required by virtually all payers), out-of-pocket costs given the drug's $125,000-per-injection list price, and the geographic limitation of needing to travel to a certified SMA treatment center for each dose.
Patients seeking help navigating the specialty access process for nusinersen can use medfinder, a paid service that helps identify treatment resources and navigate access pathways for specialty medications.
Nusinersen is not a controlled substance and has no DEA scheduling restrictions on prescribers. However, because it requires intrathecal administration by lumbar puncture and treats a complex rare neurological disease, it is prescribed and administered exclusively by specialists with SMA expertise. The prescribing provider must be experienced in lumbar puncture procedures, and the drug must be administered at a qualified treatment facility.
Specialists who prescribe and administer nusinersen:
Pediatric neurologists — primary prescribers for infants and children with SMA Types 1 and 2
Adult neurologists — manage older adolescents and adults with SMA Types 2, 3, and 4
Neuromuscular disease specialists — subspecialists at MDA Care Centers and Cure SMA Care Centers with focused SMA expertise
Physiatrists — in some multidisciplinary SMA clinics, physiatrists with SMA expertise collaborate in patient management
Nusinersen cannot be prescribed via telehealth, as the drug must be administered in person at a certified treatment facility. Telehealth may be used for follow-up monitoring and consultations, but dosing appointments are always in-person. To find a qualified treatment center, use the Cure SMA Care Center directory at curesma.org or the MDA Care Center locator at mda.org.
No. Nusinersen (Spinraza) is not a controlled substance and has no DEA scheduling. It is not subject to the prescription quantity limits, special tracking requirements, or refill restrictions that apply to scheduled controlled substances such as stimulants or opioids.
However, nusinersen is a specialty biologic and still requires a prescription from a qualified physician. It also requires prior authorization from insurance before each course of therapy. The fact that it is not a controlled substance does not reduce the administrative requirements for access — those exist because of the drug's extreme cost and specialty administration requirements, not because of addiction or abuse potential.
The most commonly reported adverse reactions from clinical trials include:
Respiratory infections (lower and upper) — most common overall adverse event
Fever
Constipation
Headache (most commonly reported verbal symptom in older patients)
Vomiting
Back pain (often procedure-related)
Post-lumbar puncture syndrome
Atelectasis (partial lung collapse; 18% in infantile-onset SMA patients)
Serious side effects requiring immediate attention:
Thrombocytopenia (low platelet count) and coagulation abnormalities — increased bleeding risk; occurs in approximately 16% of treated patients
Kidney toxicity including potentially fatal glomerulonephritis — 58% of treated patients had elevated urine protein in studies
Meningitis (serious infection associated with lumbar puncture — rare post-marketing)
Hypersensitivity reactions (angioedema, urticaria, rash)
Hydrocephalus (post-marketing reports; causal relationship unclear)
Growth reduction in infants (potential effect on height)
Know what you need? Skip the search.
Risdiplam (Evrysdi)
Oral liquid SMN2 splicing modifier; taken daily at home; approved for patients 2 months and older; no injections required. Indirect comparisons suggest comparable or potentially superior outcomes in Type 1 SMA vs. nusinersen.
Onasemnogene abeparvovec IV (Zolgensma)
One-time IV gene therapy delivering a functional SMN1 gene; approved for children under 2 years old; list price ~$2.1 million one-time cost. Designed to address the root genetic cause of SMA.
Onasemnogene abeparvovec IT (Itvisma)
One-time intrathecal gene therapy; FDA-approved November 2025 for patients aged 2 and older. Expands gene therapy access to broader age range than IV Zolgensma. May benefit patients who have plateaued on ongoing SMN2-modifying therapies.
Prefer Nusinersen? We can find it.
Anticoagulants (warfarin, heparin, rivaroxaban, apixaban)
moderateNo direct pharmacokinetic interaction, but nusinersen increases bleeding risk via thrombocytopenia. Concurrent use increases overall bleeding risk, particularly at the lumbar puncture site.
Antiplatelet agents (aspirin, clopidogrel, ticagrelor)
moderateAdditive risk of bleeding when combined with nusinersen's thrombocytopenia-causing potential. Disclose to provider before each dose; may require temporary hold around injection time.
NSAIDs (ibuprofen, naproxen)
minorMild antiplatelet effect and potential nephrotoxicity may compound nusinersen's kidney toxicity risk with regular use. Occasional use is generally acceptable; regular high-dose use should be reviewed with SMA specialist.
Aminoglycoside antibiotics (gentamicin, tobramycin)
moderateNephrotoxic antibiotics commonly used in SMA patients for respiratory infections. May increase kidney toxicity risk when combined with nusinersen. Monitor kidney function closely.
Other SMA disease-modifying therapies (risdiplam, Zolgensma, Itvisma)
majorConcurrent use of multiple SMA disease-modifying therapies is not standard practice, not supported by clinical evidence, and typically prohibited by insurance coverage policies.
Nusinersen (Spinraza) transformed the treatment of spinal muscular atrophy when it was approved in December 2016 as the first-ever disease-modifying therapy for SMA. In nearly a decade of clinical use, it has built an unparalleled safety and efficacy record — with real-world data in patients treated for up to 10 years supporting its use across ages and SMA types. The March 2026 FDA approval of the High Dose Regimen (50 mg/28 mg) further expands the options available to patients and clinicians.
The primary challenges with nusinersen are access-related rather than supply-related. The drug's extraordinary cost ($125,000 per injection), mandatory prior authorization requirements, and the need for specialized treatment centers can create meaningful delays and barriers for patients. For infantile-onset SMA in particular, these delays can have irreversible clinical consequences — making financial navigation and access support a clinical priority for care teams.
Patients and families facing access barriers to nusinersen should enroll in Biogen's SMA360° patient support program (844-477-4672) and seek care at a Cure SMA or MDA certified care center. For additional help navigating the access process, medfinder is a paid service that specializes in helping patients find and access specialty medications including nusinersen.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini